A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 8,310 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,310
Previous 8,310 -0.0%
Holding current value
$0
Previous $351,000 3.42%
% of portfolio
0.0%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$40.88 - $43.27 $44,313 - $46,904
-1,084 Reduced 11.54%
8,310 $351,000
Q4 2023

Feb 14, 2024

BUY
$20.27 - $42.44 $190,416 - $398,681
9,394 New
9,394 $398,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.